Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets

Genetics of Opisthorchis viverrini-related cholangiocarcinoma

(2015) Apinya Jusakul et al.   CURRENT OPINION IN GASTROENTEROLOGY

Molecular landscape of pancreatic cancer: implications for current clinical trials

(2015) Gregory M. Heestand et al.   Oncotarget

Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups

(2015) Michele Simbolo et al.   Oncotarget

The NF1 gene revisited – from bench to bedside

(2015) Yoon-Sim Yap et al.   Oncotarget

Phase I trial of everolimus, gemcitabine and cisplatin in patients with solid tumors

(2014) Brian A. Costello et al.   INVESTIGATIONAL NEW DRUGS

New Routes to Targeted Therapy of Intrahepatic Cholangiocarcinomas Revealed by Next-Generation Sequencing

(2014) J. S. Ross et al.   ONCOLOGIST

Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications

(2014) Chaitanya R. Churi et al.   PLoS One

Cholangiocarcinoma: Molecular Pathways and Therapeutic Opportunities

(2014) Sumera Rizvi et al.   SEMINARS IN LIVER DISEASE

Palliation

(2014) Albert Amini et al.   Surgical Oncology Clinics of North America

Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials

(2013) J. W. Valle et al.   ANNALS OF ONCOLOGY

Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma

(2013) Vikram Deshpande et al.   BMC CANCER

Emerging drugs for biliary cancer

(2013) Takuji Okusaka et al.   EXPERT OPINION ON EMERGING DRUGS

Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions

(2013) Jesse S. Voss et al.   HUMAN PATHOLOGY

Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing

(2013) Garrett M Frampton et al.   NATURE BIOTECHNOLOGY

Exome sequencing identifies distinct mutational patterns in liver fluke–related and non-infection-related bile duct cancers

(2013) Waraporn Chan-on et al.   NATURE GENETICS

Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas

(2013) Yuchen Jiao et al.   NATURE GENETICS

Epidemiology and Risk Factors of Biliary Tract and Primary Liver Tumors

(2013) Mathew M. Augustine et al.   Surgical Oncology Clinics of North America

KrasG12D and p53 Mutation Cause Primary Intrahepatic Cholangiocarcinoma

(2012) M. R. O'Dell et al.   CANCER RESEARCH

Exome sequencing of liver fluke–associated cholangiocarcinoma

(2012) Choon Kiat Ong et al.   NATURE GENETICS

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

(2012) Sunil Verma et al.   NEW ENGLAND JOURNAL OF MEDICINE

HER2/neu May Not Be an Interesting Target in Biliary Cancers: Results of an Early Phase II Study with Lapatinib

(2012) Joshua Peck et al.   ONCOLOGY

Genomic and Genetic Characterization of Cholangiocarcinoma Identifies Therapeutic Targets for Tyrosine Kinase Inhibitors

(2011) Jesper B. Andersen et al.   GASTROENTEROLOGY

SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma

(2011) Anthony B. El-Khoueiry et al.   INVESTIGATIONAL NEW DRUGS

Targeted therapies for breast cancer

(2011) Michaela J. Higgins et al.   JOURNAL OF CLINICAL INVESTIGATION

First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors

(2011) Timothy A. Yap et al.   JOURNAL OF CLINICAL ONCOLOGY

Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers

(2011) Tanios Bekaii-Saab et al.   JOURNAL OF CLINICAL ONCOLOGY

The expression of phospho-AKT1 and phospho-MTOR is associated with a favorable prognosis independent of PTEN expression in intrahepatic cholangiocarcinomas

(2011) Dakeun Lee et al.   MODERN PATHOLOGY

GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway

(2011) J. J. Wallin et al.   MOLECULAR CANCER THERAPEUTICS

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping

(2011) D. R. Borger et al.   ONCOLOGIST

KRAS and PIK3CA but not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patients

(2010) Rui Feng Xu et al.   BIOMEDICINE & PHARMACOTHERAPY

Molecular mechanisms of bile duct development

(2010) Yiwei Zong et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

(2010) Yung-Jue Bang et al.   LANCET

A novel approach to biliary tract pathology based on similarities to pancreatic counterparts: Is the biliary tract an incomplete pancreas?

(2010) Yasuni Nakanuma   PATHOLOGY INTERNATIONAL

Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial

(2009) C Bengala et al.   BRITISH JOURNAL OF CANCER

A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer

(2009) Ramesh K. Ramanathan et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

The Expression of Phospho-AKT, Phospho-mTOR, and PTEN in Extrahepatic Cholangiocarcinoma

(2009) J.-Y. Chung et al.   CLINICAL CANCER RESEARCH